Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF Trial [Original Article]
Conclusions—
Patients with lower blood pressure, lower glomerular filtration rate, and more severe heart failure were at higher risk for noncompletion during the run-in period of PARADIGM-HF. Weighted analysis of key study outcomes accounting for the effect of run-in noncompletion did not alter the benefit of LCZ696 over enalapril.
Clinical Trial Registration—
URL: http://www.clinicaltrials.gov. Unique identifier: NCT01035255.
Source: Circulation: Heart Failure - Category: Cardiology Authors: Desai, A. S., Solomon, S., Claggett, B., McMurray, J. J. V., Rouleau, J., Swedberg, K., Zile, M., Lefkowitz, M., Shi, V., Packer, M. Tags: Heart Failure, Mortality/Survival Original Article Source Type: research
More News: Cardiology | Cardiovascular | Clinical Trials | Diovan | Enalapril | Eyes | Heart | Heart Failure | Study